FDA Approves Oral Iptacopan (Fabhalta) as First C3 Glomerulopathy Therapy

Published Date: 09 Apr 2025

The March 2025 approval for iptacopan marks the first for C3 glomerulopathy and is based on the APPEAR-C3G trial.

Read Full News

Latest News

Deep Dive: The Evolving GLP-1 Class Overview

The GLP-1 class now spans ten products across six indications. This clinical deep dive maps the 2026 roster to help clinicians select the right agent for established CVD, CKD, MASH, or OSA.

Revealing CKD: Early Detection Strategies to Reduce Cardiorenal Risk

Revealing CKD: Early Detection Strategies to Reduce Cardiorenal Risk

First-in-Class Drug Approved for IgA Nephropathy

It has not been established whether atacicept slows kidney function decline long-term, however

Ushering in a New Era of IgAN Care: Targeted Therapies and Evolving Guidelines

Ushering in a New Era of IgAN Care: Targeted Therapies and Evolving Guidelines

Navigating New Guidelines in IgA Nephropathy

Navigating New Guidelines in IgA Nephropathy

FDA Greenlights Novel Hypertension Pill for Tough-to-Treat Patients

Aldosterone synthase inhibitor baxdrostat indicated as add-on to other antihypertensives

Todays Updates

Hyponatremia Risk Varies Among Second-Gen Antipsychotics

Aripiprazole is associated with a lower risk for hyponatremia compared with olanzapine in patients treated with second-generation antipsychotics, a new cohort study shows.

HCT Survival Outcomes Improving in Relapsed Hodgkin Lymphoma

Researchers evaluate changes in post-transplantation outcomes among patients with relapsed or refractory Hodgkin lymphoma from 2010 to 2022.

How Much of a Cancer Drug Is Too Much?

In a recent KFF survey, 43% of US adults said they had skipped their medication in the past year because of cost.

Todays Updates

Hyponatremia Risk Varies Among Second-Gen Antipsychotics

Aripiprazole is associated with a lower risk for hyponatremia compared with olanzapine in patients treated with second-generation antipsychotics, a new cohort study shows.

HCT Survival Outcomes Improving in Relapsed Hodgkin Lymphoma

Researchers evaluate changes in post-transplantation outcomes among patients with relapsed or refractory Hodgkin lymphoma from 2010 to 2022.

How Much of a Cancer Drug Is Too Much?

In a recent KFF survey, 43% of US adults said they had skipped their medication in the past year because of cost.

Latest News

The GLP-1 class now spans ten products across six indications. This clinical deep dive maps the 2026 roster to help clinicians select the right agent for established CVD, CKD, MASH, or OSA.

Revealing CKD: Early Detection Strategies to Reduce Cardiorenal Risk

It has not been established whether atacicept slows kidney function decline long-term, however

Ushering in a New Era of IgAN Care: Targeted Therapies and Evolving Guidelines

Navigating New Guidelines in IgA Nephropathy

Aldosterone synthase inhibitor baxdrostat indicated as add-on to other antihypertensives

News All Time

APOL1 Gene and Focal Segmental Glomerulosclerosis

Genetic variants tied to increased risk are only found in those of African decent

Make the Diagnosis: Chest Pain, Dyspnea, Palpitations, and More: What’s Her Diagnosis?

A 45-year-old woman presented to the emergency department with complaints of chest pain, heart palpitations that developed earlier that day, and dyspnea that began 3 days prior and had progressed. Can you diagnose the patient?

Rewriting What We Know About Kidney Transplant Rejection

Rewriting What We Know About Kidney Transplant Rejection

First Oral Carbapenem Approved for Complicated UTIs

Tebipenem pivoxil proved noninferior to IV imipenem-cilastatin in hospitalized patients

How Did a Patient Survive a Decade With Metastatic RCC?

Surgery had beneficial role

360 Dead in Outbreak; McConnell Still Hospitalized? FDA Rejects Kidney Disease Drug

Health news and commentary gathered by MedPage Today staff

US FDA Declines to Approve Unicycive's Kidney Disease Drug

Unicycive Therapeutics said on Tuesday the U.S. drug regulator has declined to approve its drug to ⁠treat elevated phosphate levels in chronic kidney disease patients on...

The Chatbot Will See You Now: A Crisis in Trust?

When healthcare feels out of reach, Europe’s patients are turning to AI for answers — and sometimes for the confidence to medicate themselves.

Extended-Release Febuxostat Beats Standard Drug for Gout

A new 24-hour version of febuxostat lowers uric acid levels significantly better than the standard drug for patients with severe gout, though it may carry a higher risk of serious side effects.

Mineralys' Pill Cuts Blood Pressure in Kidney Disease Patients

Mineralys Therapeutics' experimental drug significantly reduced blood pressure in patients with chronic kidney disease, according to new data presented ⁠at a major European...

Project Aims for Awareness of APOL1-Mediated Kidney Disease

The EMBARK Awareness initiative is working to raise awareness of APOL-1 mediated kidney disease among high-risk populations and medical trainees.

APOL1-Mediated Kidney Disease: Managing Family Discussions, Testing, and Implications

APOL1-Mediated Kidney Disease: Managing Family Discussions, Testing, and Implications

Navigating APOL1 Genetic Testing: Counseling Patients and Their Families

Navigating APOL1 Genetic Testing: Counseling Patients and Their Families

Critical Bedside Moments in HRS-AKI: From Recognizing Risk to Treatment Initiation

Critical Bedside Moments in HRS-AKI: From Recognizing Risk to Treatment Initiation

Changing the Course of HRS-AKI: Guideline-Directed Approaches to Optimize Treatment

Changing the Course of HRS-AKI: Guideline-Directed Approaches to Optimize Treatment

Entering a New Era of Opportunity for APOL1-Mediated Kidney Disease (AMKD): Connecting Genetic Screening to Clinical Trials for Breakthrough Therapies

Entering a New Era of Opportunity for APOL1-Mediated Kidney Disease (AMKD): Connecting Genetic Screening to Clinical Trials for Breakthrough Therapies

Recommended News For You

Mobile prostate cancer screening clinic can ID the disease in disadvantaged men

A three-quarters reduction in the risk of prostate cancer is associated with an annual increase in cardiorespiratory fitness of more than three percent.

Vepdegestrant Earns FDA Nod for ESR1-Mutated Breast Cancer

New study elucidates obesity's role in fueling breast cancer progression

Improved end-of-life conversations for cancer patients are identified by a new study.

Adaptive SABR-Used Hypofractionated Chemoradiation Showed Good Results in NSCLC.

Datopotamab Deruxtecan Earns New Breast Cancer Indication

Recommended Articles For You

Cracking the Code of Subdural Hematomas: Modern Strategies for Optimal Care 

Stomach Cancer: Uncovering the Subtle Signs and Symptoms 

Transformative Approaches in Hematology for Healthcare Excellence 

Cancer Stem Cells: The Seeds of Tumorigenesis and Recurrence 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Aspirin Fails to Boost Survival in Colorectal Cancer Trial

2.

Do Anatomy Atlases Reflect Social Inequalities?

3.

A higher risk of chemotherapy-induced peripheral neuropathy is associated with a deficiency in vitamin D prior to treatment.

4.

Some triple negative breast cancers might be avoided by longer breastfeeding

5.

Quizartinib Benefit in AML Limited to FLT3-Mutated Subgroup

1.

Innovative Intraoperative Therapies in Neurosurgical Oncology: Advancing Precision and Outcomes

2.

Metabolic Competition Within the Tumor Ecosystem: Mechanisms, Clinical Relevance, and Therapeutic Advances

3.

Ferroptosis-Modulating Nanocarriers for Solid Tumor Therapy

4.

Unlocking the Mystery of Glanzmann Thrombasthenia: A New Hope for Patients

5.

KEYNOTE-826: Optimizing Outcomes in Persistent, Recurrent, or Metastatic Cervical Cancer

1.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

2.

International Cancer Conference

3.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

4.

Asian Symposium on Advancement in Hematology and Oncology

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Clinical Excellence in Hematology

2.

Navigating the Complexities of Ph Negative ALL - Part I

3.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VII

4.

Cost Burden/ Burden of Hospitalization For R/R ALL Patients

5.

Understanding the causes of anemia in adults beyond nutritional deficiencies

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot